Vaxgen is a biopharmaceutical company focused on the development, manufacture and commercialization of biologic products for the prevention and treatment of human infectious disease. Co....
For sudden twists of fate, abrupt collapses and the occasional stunning revival, it's hard to beat the biotech industry. Yesterday, for instance, the all-but-dead biotech VaxGen agreed to sell off its ailing anthrax vaccine to its East Coast rival Emergent BioSolutions --a company that spent much of this decade trying...
Governance changes intended to support renewed strategic transaction effort SOUTH SAN FRANCISCO, Calif., May 22 /PRNewswire-FirstCall/ VaxGen, Inc. (BULLETIN BOARD: VXGN) , a biopharmaceutical company, today announced the appointment of two new members to its Board of Directors, and the resignations of three of its current Directors....
Matthew J. Pfeffer has joined the Valencia headquarters of MannKind Corp., a biopharmaceutical company that focuses on therapeutic products for diabetes and cancer, as corporate vice president and chief financial officer. Pfeffer was previously chief financial officer and senior vice president of finance and administration of VaxGen Inc., a San...
SOUTH SAN FRANCISCO, Calif., May 14 /PRNewswire-FirstCall/ -- VaxGen, Inc. (BULLETIN BOARD: VXGN) , a biopharmaceutical company, today provided guidance on its expected monthly cash expenditures following the most recent restructuring undertaken on April 9, 2008. VaxGen expects that its average monthly cash expenditures going forward are...
Acquisition positions Emergent to offer the U.S. Government a domestic source for an advanced anthrax vaccine candidate to meet planned procurement of 25 million doses of rPA vaccine ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed the acquisition of all assets and...
SOUTH SAN FRANCISCO, Calif., May 5 /PRNewswire-FirstCall/ -- VaxGen, Inc. (BULLETIN BOARD: VXGN.OB) , a biopharmaceutical company, announced today it has completed the sale of all assets and rights related to its recombinant protective antigen rPA anthrax vaccine product candidate and related technology to Emergent BioSolutions, Inc. ...
VALENCIA, Calif., April 16 /PRNewswire-FirstCall/ -- MannKind Corporation today announced that Matthew J. Pfeffer will join the company as Corporate Vice President and Chief Financial Officer, effective April 21, 2008. Mr. Pfeffer will report to Hakan Edstrom, President and Chief Operating Officer, and will serve on MannKind's executive...
M2 PRESSWIRE-1 April 2008-Wall Street News Alert: Aggressive Stock Alert: UDTT! April 1, 2008C1994-2008 M2 COMMUNICATIONS LTD RDATE:01042008 Weston, FLA. -- Wall Street News Alert's "stocks to watch" this morning are: Universal Detection Technology (OTCBB: UDTT), Grant Life Sciences...
M2 PRESSWIRE-28 March 2008-The Maybach Journal: VaxGen Inc. Review in ProgressC1994-2008 M2 COMMUNICATIONS LTD RDATE:28032008 MaybachFinancial.com is one of the fastest growing independent and unbiased research firms in the world. Investors wanting to know the truth about investing and...
M2 PRESSWIRE-28 March 2008-Market Review: Progressive Following on VaxGen Inc.C1994-2008 M2 COMMUNICATIONS LTD RDATE:29032008 Streetinvesting.com has now resumed our progressive review of VaxGen Inc. (OTCBB:VXGN) as it opened up $0.03 nearing its 52 week low of $0.41 on above...
Harnessing New Therapeutic Opportunities as Vaccine Trial Failures Mount WEST HAVEN, Conn. -- NanoViricides, Inc. (OTC BB: NNVC.OB), announced today that preliminary animal trials of HivCide-I[TM], the Company's proposed HIV therapeutic, will begin soon at a BSL-3 facility in Boston, MA. The initial results are expected by the...
ISS Recommends Vote Against the Merger with Raven and the New Equity Incentive Plan SAN FRANCISCO -- MedCap Management & Research LLC and its affiliates ("MedCap"), a substantial VaxGen Inc. VXGN shareholder, today announced that it agrees entirely with the newly published recommendations by RiskMetrics Group/ISS Governance Services....
Stock Price Decline of 40% in the Past 45 Days Shows No "Momentum" for Proposed Raven Transaction; Current Balance Sheet Working Capital is $2.01 Per Share SAN FRANCISCO -- MedCap Management & Research LLC and its affiliates ("MedCap"), a substantial VaxGen Inc. VXGN shareholder, urge all VaxGen shareholders...
M2 PRESSWIRE-17 March 2008-MB Alerts: VaxGen Inc. Review in ProgressC1994-2008 M2 COMMUNICATIONS LTD RDATE:17032008 MaybachFinancial.com is one of the fastest growing independent and unbiased research firms in the world. Investors wanting to know the truth about investing and how...
M2 PRESSWIRE-3 March 2008-BUYINS.NET: VVTV, ALMY, AVAL, EFGU, VXGN, VCTY Have Also Been Removed From Naked Short List TodayC1994-2008 M2 COMMUNICATIONS LTD RDATE:03032008 BUYINS.NET, www.buyins.net, announced today that these select companies have been removed from the NASDAQ, AMEX and...
M2 PRESSWIRE-15 February 2008-BUYINS.NET: AITX, VXGN Have Also Been Added To Naked Short List TodayC1994-2008 M2 COMMUNICATIONS LTD RDATE:15022008 BUYINS.NET, www.buyins.net, announced today that these select companies have been added to the NASDAQ, AMEX and NYSE naked short threshold...
TheSUBWAY.com announces the following stocks toits Action List: China America Holdings, Inc. (OTCBB: CAAH), JDS UniphaseCorp. (NASDAQ: JDSU), iVoice Technology, Inc. (OTCBB: IVOT), VaxGen, Inc.(PINKSHEETS: VXGN). Visit TheSUBWAY's Small Cap Investor Forum Here: http://www.thesubway.com/small-cap-forum/ to discuss our daily stock picksthroughout the trading day! China America Holdings, Inc. (OTCBB:...
M2 PRESSWIRE-22 January 2008-TheSubway.com: Stock Market Alerts Speak with Other Investors about STHG TheSUBWAYs New Small Cap Investor Forum: FEED Announces New Vice President of Technology!C1994-2008 M2 COMMUNICATIONS LTD RDATE:22012008 Visit TheSUBWAY's Small Cap Investor Forum Here:...
Stock Has Declined 46% Since November 12, 2007 Announcement of Proposed Merger SAN FRANCISCO -- MedCap Management & Research LLC ("MedCap"), a substantial VaxGen Inc. VXGN shareholder, in a letter to VaxGen's board of directors, has informed VaxGen that MedCap opposes VaxGen's proposed merger with Raven biotechnologies, inc....
Articles 2007-12-26
<< Previous
page 1 of 1
Next >>
Premier Vendor Content
Whitepapers, webcasts & resources from our Power Center Sponsors
